Primary Site >> Biliary tract Cancer
Gene >> EGFR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Simultaneous detection of epidermal growth factor receptor (EGF-R), epidermal growth factor (EGF) and ras p21 in cholangiocarcinoma by an immunocytochemical method. PMID: 2839749 |
Ref: [Immunohistochemical study of epidermal growth factor receptor and c-erbB.2 oncogene product in bile duct carcinoma: preliminary report]. PMID: 1980521 |
Ref: Serum levels of c-erbB-2 protein in digestive diseases. PMID: 7528080 Ref: Expression of epidermal growth factor receptor in gallbladder cancer. PMID: 8088775 |
Ref: Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. PMID: 8822109 |
Ref: An animal model of benign bile-duct stricture, sclerosing cholangitis and cholangiocarcinoma and the role of epidermal growth factor receptor in ductal proliferation. PMID: 8640617 Ref: Overexpression of different members of the type 1 growth factor receptor family and their association with cell proliferation in periampullary carcinoma. PMID: 8683379 Ref: Hereditary onset of multiple seborrheic keratoses: a variant of Leser Trelat sign? PMID: 8935630 |
Ref: Transforming growth factor alpha immunoreactivity in human gallbladder and extrahepatic biliary tract tumours. PMID: 9542514 Ref: c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. PMID: 9822921 |
Ref: Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. PMID: 11261824 Ref: Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. PMID: 11585718 |
Ref: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. PMID: 11910351 Ref: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. PMID: 12044528 |
Ref: [Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma]. PMID: 12654182 Ref: Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. PMID: 12846405 |
Ref: A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. PMID: 14648071 Ref: [The expression and their significance of epidermal growth factor, transforming growth factor alpha and epidermal growth factor receptor during the intrahepatic cholangiocarcinoma carcinogenesis]. PMID: 14761293 Ref: Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. PMID: 15213623 Ref: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. PMID: 15519654 Ref: Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. PMID: 15566522 |
Ref: [Expression of epidermal growth factor receptor, ErbB2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma]. PMID: 15665568 Ref: Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. PMID: 15833824 Ref: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. PMID: 15921858 Ref: Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. PMID: 16032426 Ref: Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. PMID: 16061875 Ref: Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions. PMID: 16116640 Ref: Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer. PMID: 19956499 |
Ref: The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines. PMID: 16525641 Ref: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. PMID: 16551849 Ref: Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. PMID: 16891476 Ref: Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. PMID: 16926628 Ref: Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. PMID: 17079474 |
Ref: Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. PMID: 17341899 Ref: Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. PMID: 17551669 Ref: Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. PMID: 17575102 Ref: Expression of c-erbB-2 proto-oncogene in extrahepatic cholangiocarcinoma and its clinical significance. PMID: 17690040 Ref: Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. PMID: 17708250 Ref: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. PMID: 18025804 Ref: HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. PMID: 19262900 |
Ref: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. PMID: 18087285 Ref: Diagnosis and management of cholangiocarcinoma. PMID: 18417042 Ref: EGFR expression in gallbladder carcinoma in North America. PMID: 18825277 Ref: Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. PMID: 19084911 |
Ref: A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. PMID: 19262069 Ref: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. PMID: 19319137 Ref: Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. PMID: 19331129 Ref: ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. PMID: 19376120 Ref: ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines. PMID: 19414361 Ref: Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. PMID: 19509244 Ref: EGFR and HER2 expression in advanced biliary tract cancer. PMID: 19777609 Ref: Targeted therapy in biliary tract cancer: 2009 update. PMID: 20001803 |
Ref: Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. PMID: 20040392 Ref: Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. PMID: 20164661 Ref: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. PMID: 20388063 Ref: Chemotherapy in biliary tract cancer. PMID: 20496551 Ref: Gallbladder cancer with tumor thrombus in the superior vena cava. PMID: 20525563 Ref: Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. PMID: 20530271 Ref: Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. PMID: 20565817 Ref: Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. PMID: 20607690 Ref: Advances in the treatment of metastatic or unresectable biliary tract cancer. PMID: 20943640 Ref: Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. PMID: 20961434 |
Ref: The prognostic relevance of tumor hypoxia markers in resected carcinoma of the gallbladder. PMID: 21109386 Ref: Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PMID: 21253578 Ref: Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. PMID: 21472131 Ref: Genetics of hepatobiliary carcinogenesis. PMID: 21538283 Ref: Clinical relevance of epidermal growth factor receptor (EGFR) alterations in human pancreatic tumors. PMID: 21573507 Ref: Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. PMID: 21673683 |
Ref: EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact. PMID: 21761100 Ref: L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. PMID: 22088438 Ref: Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. PMID: 22178589 Ref: Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. PMID: 22210086 Ref: Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma. PMID: 22246855 Ref: Clinicopathological significance of E-cadherin, beta-catenin and epidermal growth factor receptor expression in intrahepatic cholangiocarcinoma. PMID: 22281980 Ref: Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells. PMID: 22591401 Ref: Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells. PMID: 23225424 |
Ref: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. PMID: 23391413 Ref: EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PMID: 23704979 Ref: Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor. PMID: 23787814 Ref: Expression levels and significance of nuclear factor-kappaB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma. PMID: 24008372 Ref: A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. PMID: 24146220 Ref: [The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab]. PMID: 24393913 |
Ref: Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. PMID: 23828315 Ref: Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. PMID: 24081803 Ref: High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. PMID: 24186137 Ref: Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. PMID: 24186143 Ref: Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. PMID: 24372748 Ref: Molecular aspects of cholangiocarcinoma. PMID: 24420749 Ref: Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PMID: 24550739 Ref: Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. PMID: 24551272 Ref: EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. PMID: 24704591 Ref: Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. PMID: 24787096 Ref: Epstein-Barr virus-associated lymphoepithelioma-like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. PMID: 24804938 Ref: [Nuclear translocation of epidermal growth factor receptor and its relation to clinicopathological factors in oral squamous cell carcinomas]. PMID: 24812767 Ref: A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done. PMID: 24857099 Ref: Characterization of EGFR family gene aberrations in cholangiocarcinoma. PMID: 24927194 Ref: Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. PMID: 24960403 Ref: Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. PMID: 24997986 Ref: Evaluation of P53, E-cadherin, Cox-2, and EGFR protein immunoexpression on prognostic of resected gallbladder carcinoma. PMID: 25004291 Ref: SOX4 is associated with poor prognosis in cholangiocarcinoma. PMID: 25181339 Ref: The ERBB pathway is recurrently mutated in gallbladder carcinoma. PMID: 25185194 Ref: Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer. PMID: 25217982 Ref: Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma. PMID: 25225463 Ref: Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma. PMID: 25336976 Ref: Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. PMID: 25341559 Ref: Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PMID: 25536104 |
Ref: Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer. PMID: 24839254 Ref: Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. PMID: 25639632 Ref: Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. PMID: 25749176 Ref: MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor. PMID: 25760482 Ref: Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia. PMID: 25770659 Ref: Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. PMID: 25815516 Ref: Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. PMID: 25879652 Ref: Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies. PMID: 25966433 Ref: Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). PMID: 25975284 Ref: Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats. PMID: 26028817 Ref: Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. PMID: 26111977 Ref: Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PMID: 26207380 Ref: Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population. PMID: 26550313 Ref: Dual role of CD44 isoforms in ampullary adenocarcinoma: CD44s predicts poor prognosis in early cancer and CD44nu is an indicator for recurrence in advanced cancer. PMID: 26572077 Ref: Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. PMID: 26656516 |
Ref: Lupeol induces apoptosis and inhibits invasion in gallbladder carcinoma GBC-SD cells by suppression of EGFR/MMP-9 signaling pathway. PMID: 25037728 Ref: Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma. PMID: 26405193 Ref: Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). PMID: 26540314 Ref: Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. PMID: 26857926 Ref: Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. PMID: 26868125 Ref: EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. PMID: 27020207 Ref: EGFR and HER-2/neu Expression in Gallbladder Carcinoma: An Institutional Experience. PMID: 27050174 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. PMID: 27136744 Ref: The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. PMID: 27317099 Ref: TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. PMID: 27335026 Ref: Epidermal growth factor receptor expression in carcinoma gallbladder: A prospective study in Indian scenario. PMID: 27461681 Ref: Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials. PMID: 27537589 Ref: Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. PMID: 27593557 Ref: Molecular characteristics of biliary tract cancer. PMID: 27823638 Ref: Systemic therapy for biliary cancers. PMID: 27829278 Ref: Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. PMID: 27902465 Ref: KRAS Mutation as a Potential Prognostic Biomarker of Biliary Tract Cancers. PMID: 28008299 |
Ref: Whole-genome sequencing reveals the mutational landscape of metastatic small-cell gallbladder neuroendocrine carcinoma (GB-SCNEC). PMID: 28040546 Ref: Intrahepatic cholangiocarcinoma: current perspectives. PMID: 28260927 Ref: The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. PMID: 28285962 Ref: Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials. PMID: 28397047 Ref: Integrated mRNA and lncRNA expression profiling for exploring metastatic biomarkers of human intrahepatic cholangiocarcinoma. PMID: 28401021 Ref: Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. PMID: 28412732 Ref: Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. PMID: 28459363 Ref: Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer. PMID: 28624624 Ref: Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. PMID: 28671339 Ref: Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma. PMID: 28729631 Ref: Current biologics for treatment of biliary tract cancers. PMID: 28736630 Ref: HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2. PMID: 28768863 Ref: INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. PMID: 28801995 Ref: Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma. PMID: 28843919 Ref: Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients. PMID: 28900470 Ref: Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. PMID: 28975832 |
Ref: Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers. PMID: 29138340 Ref: Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PMID: 29352306 Ref: PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study. PMID: 29413685 Ref: Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. PMID: 29416916 Ref: Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. PMID: 29551704 Ref: Investigation of targetable predictive and prognostic markers in gallbladder carcinoma. PMID: 29564177 Ref: Human epidermal growth factor receptor 2, epidermal growth factor receptor, and c-MET overexpression and survival in biliary tract cancer: A meta-analysis. PMID: 29578146 Ref: Mucinous intrahepatic cholangiocarcinoma: a distinct variant. PMID: 29698701 Ref: EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs. PMID: 29721058 Ref: Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. PMID: 29805522 Ref: Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. PMID: 29954840 Ref: ERBB2 and KRAS Alterations Mediate Response to EGFR Inhibitors in Early Stage Gallbladder Cancer. PMID: 30304546 |